Prokidney Corp
PROK
NASDAQ
Biotechnology
$1.33
USD
-0.08 (-5.34%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $424.02M
Volume 1.4M
Revenue
$818,000
TTM
+55.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-165.75M
TTM
-0.8%
YoY
Operating Cash Flow
$-141.17M
TTM
-23.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
YoY Growth | — | — | +196.1% | -1.7% | -32.1% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 |
Selling, General & Administrative | 14.0 | 11.9 | 11.4 | 11.3 | 12.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 39.9 | 38.8 | 45.6 | 45.2 | 48.5 |
Operating Income | -39.7 | -38.5 | -45.4 | -44.9 | -48.4 |
EBITDA | -38.2 | -36.9 | -43.5 | -43.3 | -46.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 3.6 | 3.3 | 2.9 | 2.3 | 1.9 |
Income Before Income Taxes | -36.1 | -35.3 | -42.4 | -42.6 | -46.4 |
Income Taxes | 0.8 | 0.6 | -1.6 | 0.0 | 0.0 |
Net Income | -37.0 | -35.8 | -40.9 | -42.6 | -46.4 |
Consolidated Net Income / Loss | -37.0 | -35.8 | -40.9 | -42.6 | -46.4 |
Net Income Attributable to Common Shareholders | -16.6 | -16.5 | -19.2 | -20.0 | -28.4 |
Basic EPS | -$0.13 | -$0.12 | -$0.13 | -$0.14 | -$0.15 |
Diluted EPS | -$0.13 | -$0.12 | -$0.13 | -$0.14 | -$0.15 |
Basic Shares Outstanding | 130.7M | 135.0M | 143.1M | 141.9M | 186.6M |
Diluted Shares Outstanding | 130.7M | 135.0M | 143.1M | 141.9M | 186.6M |